Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dermategrity Everyday Barrier Cream** is an investigational topical barrier-cream formulation developed by ScotiaDerm for moisture-associated skin damage associated with fecal incontinence and diarrhea. The formulation contains zinc oxide plus a soybean-derived plant extract described as inhibiting fecal enzymes. It is intended to form a protective cutaneous barrier while reducing enzyme-mediated breakdown of compromised skin. It is being evaluated against standard zinc oxide barrier cream in registered randomized clinical studies. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06370637))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermategrity Everyday Barrier Cream.